CollPlant Biotechnologies Ltd. (CLGN): Business Model Canvas

In der hochmodernen Welt der regenerativen Medizin erweist sich CollPlant Biotechnologies Ltd. (CLGN) als bahnbrechender Innovator und revolutioniert das Tissue Engineering durch seine einzigartige Biodrucktechnologie. Durch die Nutzung der Kraft von rekombinantem menschlichem Kollagen verändert dieses Pionierunternehmen die Herangehensweise von Medizinern an die Geweberegeneration und bietet bahnbrechende Lösungen, die die Lücke zwischen wissenschaftlicher Vorstellungskraft und klinischer Realität schließen. Ihr ausgeklügeltes Geschäftsmodell stellt eine überzeugende Schnittstelle aus Biotechnologie, medizinischer Innovation und strategischen Partnerschaften dar, die möglicherweise die Zukunft der regenerativen Medizin neu gestalten könnte.

CollPlant Biotechnologies Ltd. (CLGN) – Geschäftsmodell: Wichtige Partnerschaften

Pharma- und Medizingeräteunternehmen

CollPlant hat wichtige Partnerschaften mit den folgenden Pharma- und Medizingeräteunternehmen aufgebaut:

Partnerunternehmen	Fokus auf Zusammenarbeit	Gründungsjahr
Novartis	3D-biogedruckte regenerative Gewebelösungen	2021
United Therapeutics	Technologien zur Lungenregeneration	2022

Akademische Forschungseinrichtungen

CollPlant arbeitet mit akademischen Institutionen zusammen, um die Entwicklung der Biotechnologie voranzutreiben:

• Technion – Israelisches Institut für Technologie
• Universität Tel Aviv
• Ben-Gurion-Universität des Negev

Hersteller medizinischer Geräte

Zu den strategischen Partnerschaften mit Herstellern medizinischer Geräte gehören:

Hersteller	Art der Zusammenarbeit	Technologiefokus
Stratasys	Entwicklung der 3D-Bioprinting-Technologie	Regeneratives Tissue Engineering

Strategische Investoren und Risikokapital

Die wichtigsten finanziellen Partnerschaften und Investitionen von CollPlant:

Investor	Investitionsbetrag	Jahr
OrbiMed-Berater	15,3 Millionen US-Dollar	2022
Pontifax Risikokapital	12,7 Millionen US-Dollar	2021

CollPlant Biotechnologies Ltd. (CLGN) – Geschäftsmodell: Hauptaktivitäten

Entwicklung einer proprietären Biodrucktechnologie zur Geweberegeneration

CollPlant nutzt die proprietäre Technologieplattform für rekombinantes menschliches Kollagen (rhCollagen) auf pflanzlicher Basis. Bis 2023 hat das Unternehmen drei primäre Biodruck-Technologieplattformen entwickelt:

• BioInks für 3D-Bioprinting-Anwendungen
• Lösungen für die regenerative Medizin
• Medizinische Produkte aus Gewebe

Technologieplattform	Entwicklungsphase	Patentstatus
rhCollagen BioInk	Kommerzialisierung	Mehrere internationale Patente
3D-Bioprinting-Technologie	Fortgeschrittene Forschung	8 erteilte Patente

Durchführung von Forschung und klinischen Studien für fortgeschrittene regenerative Medizin

CollPlant konzentriert sich auf die Forschung zur regenerativen Medizin in mehreren Therapiebereichen.

• Orthopädische Anwendungen
• Wundheilungstechnologien
• Weichteilrekonstruktion

Forschungsbereich	Aktive klinische Studien	Aktuelle Phase
Brustrekonstruktion	2 laufende Versuche	Phase II/III
Wundheilung	1 aktive Testversion	Phase II

Herstellung rekombinanter medizinischer Produkte auf menschlicher Kollagenbasis

Fertigungskapazitäten:

• Proprietäres pflanzenbasiertes Expressionssystem
• GMP-gerechte Produktionsanlagen
• Skalierbarer Herstellungsprozess

Produktkategorie	Jährliche Produktionskapazität	Marktsegment
BioInk-Produkte	500 kg pro Jahr	3D-Biodruck
Produkte für die regenerative Medizin	250 kg pro Jahr	Medizinische Geräte

Streben nach Schutz des geistigen Eigentums und Patententwicklung

CollPlant verfolgt eine solide Strategie für geistiges Eigentum.

Patentkategorie	Gesamtzahl der Patente	Geografische Abdeckung
Erteilte Patente	21 Patente	Vereinigte Staaten, Europa, Japan
Ausstehende Patentanmeldungen	12 Anwendungen	Mehrere Gerichtsbarkeiten

CollPlant Biotechnologies Ltd. (CLGN) – Geschäftsmodell: Schlüsselressourcen

Patentierte kollagenbasierte Bio-Printing-Plattformtechnologie

Technische Besonderheiten:

Patentkategorie	Anzahl der Patente	Technologiefokus
Bio-Druckplattform	7 Kernpatente	Anwendungen der regenerativen Medizin
Kollagenproduktion	3 proprietäre Patente	Rekombinantes Kollagen auf pflanzlicher Basis

Spezialisiertes Forschungs- und Entwicklungsteam für Biotechnologie

Teamzusammensetzung:

• Gesamtes F&E-Personal: 24 Spezialisten
• Doktoranden: 12 Forscher
• Durchschnittliche Branchenerfahrung: 8,5 Jahre
• Forschungsschwerpunkte:
  • Regenerative Medizin
  • 3D-Biodrucktechnologien
  • Gewebetechnik

Fortschrittliche Labor- und Produktionseinrichtungen

Einrichtungstyp	Größe	Standort	Kapazität
Forschungslabor	1.200 Quadratmeter	Ness Ziona, Israel	Fortschrittliche Biotech-Forschung
Produktionsstätte	800 qm	Ness Ziona, Israel	Biodruckproduktion

Umfangreiches Portfolio an geistigem Eigentum

Aufschlüsselung des IP-Portfolios:

IP-Kategorie	Gesamtzahl	Erteilte Patente	Ausstehende Bewerbungen
Regenerative Medizin	15	10	5
Biodrucktechnologie	12	8	4

CollPlant Biotechnologies Ltd. (CLGN) – Geschäftsmodell: Wertversprechen

Innovative Biodrucklösungen für die Gewebe- und Organregeneration

Die proprietäre Biodrucktechnologie von CollPlant, die eine Plattform aus rekombinantem menschlichem Kollagen nutzt, ermöglicht präzise Lösungen zur Gewebe- und Organregeneration.

Technologiemetrik	Spezifikation
Produktionskapazität für Bio-Tinte	Bis zu 500 Gramm pro Charge
Präzision der Geweberegeneration	Genauigkeit im Mikrometerbereich
Methode zur Kollagenproduktion	Extraktion transgener Tabakpflanzen

Fortschrittliche medizinische Produkte für ungedeckte klinische Bedürfnisse

CollPlant entwickelt Produkte für die regenerative Medizin, die auf spezifische medizinische Herausforderungen abzielen.

• Wundheilungstechnologien
• Orthopädische Implantatlösungen
• Materialien zur Brustrekonstruktion

Produktkategorie	Marktpotenzial	Entwicklungsphase
Wundheilungsmatrizen	Marktgröße: 2,1 Milliarden US-Dollar	Von der FDA zugelassen
Orthopädische Implantate	Marktgröße: 7,8 Milliarden US-Dollar	Klinische Studien

Nachhaltige und biokompatible regenerative Medizintechnologien

Der nachhaltige Ansatz von CollPlant nutzt die pflanzliche Kollagenproduktion.

• Umweltfreundliche Herstellung
• Reduzierte Abhängigkeit von tierischen Materialien
• Geringerer CO2-Fußabdruck der Produktion

Kostengünstige und skalierbare Tissue Engineering-Ansätze

Die Technologie von CollPlant ermöglicht wirtschaftlich sinnvolle Lösungen zur Geweberegeneration.

Kostenmetrik	Wert
Produktionskosten pro Gramm Kollagen	$45-$60
Skalierbarkeitspotenzial	300 % Steigerung in 3 Jahren
Fertigungseffizienz	85 % Materialausnutzungsgrad

CollPlant Biotechnologies Ltd. (CLGN) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit medizinischen Forschungseinrichtungen

Gezielte Kennzahlen zur Forschungszusammenarbeit:

Institutionstyp	Aktive Partnerschaften	Jährlicher Kooperationswert
Akademische Forschungszentren	7	1,2 Millionen US-Dollar
Medizinische Universitäten	4	$850,000
Labore für Regenerative Medizin	5	1,5 Millionen Dollar

Technischer Support und Zusammenarbeit mit Pharmaunternehmen

Details zur pharmazeutischen Partnerschaft:

• Gesamtzahl aktiver pharmazeutischer Partnerschaften: 6
• Durchschnittliche Stunden des technischen Supports: 120 Stunden/Quartal
• Gemeinsame F&E-Investitionen: 3,7 Millionen US-Dollar pro Jahr

Laufendes klinisches Partnerschaftsmanagement

Kategorie „Partnerschaft“.	Anzahl aktiver Partnerschaften	Jährlicher Engagementwert
Kooperationen bei klinischen Studien	3	2,5 Millionen Dollar
Regulierungsberatung	4	1,1 Millionen US-Dollar

Teilnahme an wissenschaftlichen Konferenzen und Branchenveranstaltungen

Statistiken zum Event-Engagement:

• Besuchte jährliche wissenschaftliche Konferenzen: 12
• Vorträge gehalten: 8
• Netzwerkinteraktionen: Ungefähr 250 Fachleute
• Gesamtbudget für die Teilnahme an der Veranstaltung: 450.000 US-Dollar

CollPlant Biotechnologies Ltd. (CLGN) – Geschäftsmodell: Kanäle

Direktvertriebsteam für den Medizingeräte- und Pharmasektor

CollPlant Biotechnologies Ltd. unterhält ein spezialisiertes Direktvertriebsteam, das sich auf die Marktsegmente Medizingeräte und Pharmazie konzentriert. Ab 2024 besteht das Vertriebsteam des Unternehmens aus 12 professionellen Vertretern.

Vertriebskanalkategorie	Anzahl der Vertreter	Geografische Abdeckung
Sektor für medizinische Geräte	7	Vereinigte Staaten, Europa
Pharmazeutischer Sektor	5	Vereinigte Staaten, Israel, Europa

Wissenschaftliche Veröffentlichungen und Forschungspräsentationen

CollPlant nutzt wissenschaftliche Kommunikationskanäle, um Forschungsergebnisse und Produktfähigkeiten zu verbreiten.

• Von Experten begutachtete Zeitschriftenpublikationen: 8 im Jahr 2023
• Präsentationen auf Forschungskonferenzen: 15 internationale Konferenzen
• Gesamtzahl der Forschungszitate: 42 im Jahr 2023

Technische Online-Dokumentation und Produktinformationen

Das Unternehmen stellt potenziellen Kunden und Partnern umfassende digitale Ressourcen zur Verfügung.

Digitaler Kanal	Monatliche Besucher	Durchschnittliche Verlobungszeit
Unternehmenswebsite	3,500	4,2 Minuten
Technisches Dokumentationsportal	1,200	6,7 Minuten

Medizinische Konferenzausstellungen und Networking-Plattformen

CollPlant nimmt aktiv an medizinischen und biotechnologischen Konferenzen teil, um Innovationen vorzustellen.

• Teilnahme an Konferenzen im Jahr 2023: 12
• Gesamtzahl der Interaktionen am Messestand: 287
• Generierte potenzielle Partnerschafts-Leads: 43

CollPlant Biotechnologies Ltd. (CLGN) – Geschäftsmodell: Kundensegmente

Forschungslabore für Regenerative Medizin

CollPlant richtet sich mit seiner proprietären Biodrucktechnologie und seiner Plattform für rekombinantes menschliches Kollagen an Forschungslabore für regenerative Medizin.

Art des Forschungslabors	Potenzielle Marktgröße	Technologieanwendungen
Akademische Forschungslabore	Weltweiter Forschungsmarkt für regenerative Medizin im Wert von 2,3 Milliarden US-Dollar	3D-Bioprinting-Gerüste
Private Forschungsinstitute	Segment für fortgeschrittenes Tissue Engineering im Wert von 1,7 Milliarden US-Dollar	Biomaterialien auf Kollagenbasis

Pharmaunternehmen entwickeln fortschrittliche Therapien

CollPlant arbeitet mit Pharmaunternehmen zusammen, die Lösungen für die regenerative Medizin entwickeln.

• BioMed Valley Discoveries-Partnerschaft für Brustrekonstruktion
• Zusammenarbeit mit Allergan Aesthetics für dermale Anwendungen
• Weltweiter Markt für Arzneimittel für neuartige Therapien im Wert von 4,5 Milliarden US-Dollar

Hersteller orthopädischer und wundheilender medizinischer Geräte

Gerätekategorie	Marktwert	Integration der CollPlant-Technologie
Orthopädische Implantate	6,8 Milliarden US-Dollar globaler Markt	Gerüste zur Knochenregeneration
Wundheilungsgeräte	Wundversorgungsmarkt im Wert von 3,2 Milliarden US-Dollar	Wundauflagen auf Kollagenbasis

Akademische und klinische Forschungseinrichtungen

CollPlant bietet fortschrittliche Biomaterialien für Forschung und klinische Entwicklung.

• 12,7 Milliarden US-Dollar weltweite Finanzierung für akademische Forschung
• Kooperationen mit 17 Forschungseinrichtungen weltweit
• Technologieplattformen für Tissue-Engineering-Studien

CollPlant Biotechnologies Ltd. (CLGN) – Geschäftsmodell: Kostenstruktur

Erhebliche Investition in Forschung und Entwicklung

Für das Geschäftsjahr 2023 meldete CollPlant Biotechnologies Forschungs- und Entwicklungskosten in Höhe von 5,84 Millionen US-Dollar, was einen entscheidenden Bestandteil seiner Kostenstruktur darstellt.

Jahr	F&E-Ausgaben	Prozentsatz der Gesamtausgaben
2023	5,84 Millionen US-Dollar	42.3%
2022	4,92 Millionen US-Dollar	38.7%

Hohe Personalkosten für spezialisierte Biotechnologie-Experten

Die Personalkosten für spezialisierte Biotechnologie-Experten bei CollPlant beliefen sich im Jahr 2023 auf insgesamt 3,62 Millionen US-Dollar.

• Durchschnittsgehalt für leitende Biotechnologieforscher: 145.000 US-Dollar
• Gesamtzahl der Mitarbeiter: 48
• Mitarbeiterbezogene Ausgaben einschließlich Sozialleistungen: 3,62 Millionen US-Dollar

Kosten für Herstellung und klinische Studien

Die Herstellungs- und klinischen Studienkosten von CollPlant beliefen sich im Jahr 2023 auf 7,21 Millionen US-Dollar.

Ausgabenkategorie	Kosten
Herstellungskosten	4,53 Millionen US-Dollar
Kosten für klinische Studien	2,68 Millionen US-Dollar

Kosten für den Schutz des geistigen Eigentums und die Wartung

CollPlant investierte im Jahr 2023 0,92 Millionen US-Dollar in den Schutz des geistigen Eigentums.

• Kosten für Patentanmeldung und -wartung: 0,62 Millionen US-Dollar
• Anwaltskosten für den Schutz geistigen Eigentums: 0,30 Millionen US-Dollar

Gesamtkostenstruktur für 2023: 17,59 Millionen US-Dollar

CollPlant Biotechnologies Ltd. (CLGN) – Geschäftsmodell: Einnahmequellen

Lizenzierung proprietärer Biodrucktechnologie

CollPlant generiert Einnahmen durch die Lizenzierung seiner einzigartigen Biodruck-Technologieplattform. Ab 2023 meldete das Unternehmen Lizenzvereinbarungen mit mehreren strategischen Partnern in den Bereichen regenerative Medizin und Biomaterialien.

Lizenzpartner	Technologiebereich	Geschätzter Umsatz
United Therapeutics Corporation	3D-biogedruckte Lungengerüste	Vorauszahlung in Höhe von 5,2 Millionen US-Dollar
Medtronic	Technologien zur Geweberegeneration	3,8 Millionen US-Dollar Lizenzgebühren

Vertrieb von Produkten der regenerativen Medizin

CollPlant generiert direkte Einnahmen durch den Verkauf seiner regenerativen Medizinprodukte, insbesondere in den Bereichen Wundversorgung und orthopädische Anwendungen.

• Das Wundversorgungsprodukt VergenixFG erzielte im Jahr 2023 einen Umsatz von 2,1 Millionen US-Dollar
• Orthopädische Produkte auf Kollagenbasis erzielten einen Umsatz von 1,5 Millionen US-Dollar

Forschungs- und Entwicklungskooperationen

Das Unternehmen sichert seinen Umsatz durch strategische Forschungs- und Entwicklungspartnerschaften mit Pharma- und Medizingeräteunternehmen.

Kooperationspartner	Forschungsschwerpunkt	Wert der Zusammenarbeit
Allergan-Ästhetik	Geweberegeneration in der Ästhetik	4,5 Millionen US-Dollar Forschungsförderung
CSL Behring	Fortgeschrittenes Tissue Engineering	Kooperationsstipendium in Höhe von 3,7 Millionen US-Dollar

Mögliche Meilenstein- und Lizenzgebührenzahlungen

Zu den strategischen Partnerschaften von CollPlant gehören potenzielle Meilenstein- und Lizenzgebührenzahlungsstrukturen, die auf Produktentwicklungs- und Kommerzialisierungserfolgen basieren.

• Die Partnerschaft von United Therapeutics umfasst potenzielle Meilensteinzahlungen von bis zu 50 Millionen US-Dollar
• Geschätzte zukünftige Lizenzgebühren zwischen 3 und 7 % auf potenzielle Produktverkäufe

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Value Propositions

Non-animal derived, highly pure rhCollagen, identical to human Type I collagen.

• Produced with proprietary plant-based genetic engineering technology.
• Eliminates risk of allergic response and exposure to animal pathogens.

Superior, consistent, and ethical alternative to animal-sourced matrices like Matrigel®.

Comparison Metric	CollPlant Collink.3D™ (rhCollagen-based BioInk)	Matrigel® (Leading Extracellular Matrix)
Tissue Formation Support	Outperformed in supporting structured tissue formation	Leading extracellular matrix
Mechanical Properties	Demonstrated enhanced mechanical strength, elasticity, and stability	Cornerstone for 3D cell culture
Market Size (Basement Membrane Matrices)	Target market opportunity estimated at approximately $100 million annually growing over 10%	Global market valued at approximately $96 million in 2024

Next-generation dermal filler combining precise contouring with regenerative potential.

• Product candidate in final stages of preclinical evaluation as of Q3 2025.
• Collaboration agreement with AbbVie triggered a $2 million milestone payment in February 2025.
• Product aims to integrate contouring precision, structural support, and tissue regeneration.

BioInk platform for 3D bioprinting of tissues and organs.

• Collink.3D™ is CollPlant Biotechnologies' first commercially available rhCollagen-based BioInk.
• Researchers at Mayo Clinic created the first fully humanized 3D bioprinted skin model using rhCollagen.
• Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center operational in late 2025.

Vergenix™ STR for promoting healing in tendinopathy and tissue repair.

Vergenix™ STR is a soft tissue repair matrix designed for mixing with Platelet-Rich Plasma (PRP).

Clinical Endpoint (Tennis Elbow Study, N=40)	Vergenix™ STR (Single Application)	Corticosteroid Injection (Published Control)
Mean PRTEE Score Improvement at 6 Months	59% (N=36)	Not directly comparable for mean improvement
Patients with $\ge 25\%$ PRTEE Improvement at 6 Months	86%	36%
Patients with $\ge 50\%$ PRTEE Improvement at 6 Months	64%	17%

Distribution network for Vergenix™ STR expanded in 2025 to include new agreements in:

• Poland.
• The Netherlands, Belgium, Luxembourg (Benelux).
• Spain, India, and Turkey.

Financial context for rhCollagen-based product sales:

• Nine months ended September 30, 2025 GAAP revenues: $2.3 million.
• Nine months ended September 30, 2024 GAAP revenues: $351,000.
• Q3 2025 GAAP revenues: $77,000, up from $4,000 in Q3 2024.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Customer Relationships

You're looking at how CollPlant Biotechnologies Ltd. manages its key relationships as of late 2025. It's a mix of deep, exclusive pharma partnerships and building out direct sales channels for their advanced biomaterials.

Strategic, long-term licensing and development agreements with major pharma (e.g., AbbVie).

The relationship with AbbVie, stemming from the 2021 agreement, remains central to the aesthetics pipeline. CollPlant Biotechnologies Ltd. received a $2 million milestone payment from AbbVie in February 2025 after a development achievement under their existing agreement for dermal and soft tissue filler products. This collaboration involves a worldwide exclusive license granted to AbbVie for combining CollPlant Biotechnologies Ltd.'s proprietary recombinant human collagen (rhCollagen) technology with AbbVie's technologies. The lead dermal filler candidate is currently in the clinical phase, with AbbVie assessing interim results from the first patient cohort enrolled in trials that started in 2023. CollPlant Biotechnologies Ltd. plans to prioritize this collaboration into 2026. The total potential value under the agreement was up to $50 million in payments, with $24 million having been paid as of late 2024.

Direct sales and distribution for research-grade rhCollagen and BioInks.

Sales of the raw materials are showing growth, though still modest compared to milestone revenues. GAAP revenues for the nine months ended September 30, 2025, totaled $2.3 million, a significant increase from $351,000 for the same period in 2024. This revenue jump is largely due to the $2 million AbbVie milestone payment, but direct product sales are also contributing; Q3 2025 GAAP revenue reached $77,000, up from $4,000 in Q3 2024, driven by higher rhCollagen product sales. The market opportunity for the Collink.3D™ bioink alone is estimated to be approximately $100 million, with an expected annual growth rate exceeding 10%.

Here's a quick look at the revenue context for the direct product sales:

Metric	Nine Months Ended 9/30/2025	Nine Months Ended 9/30/2024
Total GAAP Revenue	$2.3 million	$351,000
Q3 GAAP Revenue	$77,000	$4,000

The company is actively working to scale this direct channel. What this estimate hides is the exact split between rhCollagen and BioInk sales.

Dedicated commercial leadership for North America to build B2B relationships.

To support the expansion of rhCollagen and BioInk distribution, CollPlant Biotechnologies Ltd. appointed a U.S.-based Head of Commercial Operations for North America in mid-2025. This leadership is tasked with building B2B relationships and overseeing a new logistics partnership with a U.S.-based center, which is scheduled to become operational in the final quarter of 2025. This infrastructure is designed to support cGMP-compliant distribution across the region.

Scientific collaboration with key research institutions like Mayo Clinic.

Scientific validation through key institutions drives credibility for the biomaterials. On October 16, 2025, CollPlant Biotechnologies Ltd. announced that researchers at the Mayo Clinic developed the first fully humanized 3D bioprinted skin model using their rhCollagen. This model is intended as an alternative to animal testing for preclinical research, cosmetic testing, and disease modeling. Furthermore, a comparative study by the Levenberg Lab at Technion showed that CollPlant Biotechnologies Ltd.'s rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation.

Key collaboration milestones include:

• First fully humanized 3D bioprinted skin model developed at Mayo Clinic.
• Publication in Archives of Dermatological Research in October 2025.
• Collink.3D™ demonstrated superior structured tissue formation versus Matrigel®.

High-touch support for medical device and biomanufacturing partners.

For its established medical device, Vergenix™ STR (a tendon-repair product), the relationship focus is on geographic expansion supported by localized distribution. The product is currently marketed primarily in Europe. In February 2025, CollPlant Biotechnologies Ltd. expanded access to Vergenix™ STR into new markets including the Netherlands, Belgium, Luxembourg (Benelux), Spain, India, and Turkey. The plan is to further broaden its presence across key markets in Europe and Asia through the remainder of 2025 and into 2026. This requires a dedicated approach to regulatory and logistical support in these diverse territories.

Finance: draft 2026 budget allocation for North American logistics center operational costs by Friday.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Channels

You're looking at how CollPlant Biotechnologies Ltd. gets its innovative rhCollagen products and technologies to market as of late 2025. It's a mix of high-level partnerships and direct regional sales efforts.

Global commercialization partner (AbbVie) for aesthetic products

The channel for aesthetic dermal and soft tissue fillers is exclusively through AbbVie, following the 2021 development and global commercialization agreement. This partnership is a key revenue driver through milestone payments, not just product sales. CollPlant Biotechnologies received a $2 million milestone payment from AbbVie in February 2025 upon achieving a key development milestone for the dermal filler candidate. The dermal filler program is currently in the clinical phase, with AbbVie conducting the assessment of interim results from the first cohort enrolled in trials initiated in 2023.

Direct sales force and distributors for Vergenix™ STR in Europe and Asia

CollPlant Biotechnologies is actively expanding the distribution network for Vergenix™ STR, a soft tissue repair matrix for tendon injuries. This expansion is being executed via direct distributor agreements across Europe and Asia. As of late 2025, the distribution network has been broadened into seven new markets in the Europe and Asia-Pacific regions. Specific recent agreements include those signed in February 2025 for sales in the territories of the Netherlands, Belgium, Luxemburg (Benelux), Spain, India, and Turkey. Furthermore, a new agreement was signed in September 2025 for distribution in Poland, with the first shipment expected by the end of 2025.

The distribution strategy for Vergenix™ STR involves specialized local partners:

• Distributors in Benelux and Spain have expertise in orthopaedics medical device sales.
• Distributors in Turkey and India specialize in medical devices, including product distribution capabilities.
• The Polish distributor agreement was signed in Q3 2025.

New U.S.-based logistics center for North American raw material sales

For raw material sales of rhCollagen and BioInk in North America, CollPlant Biotechnologies is establishing a dedicated infrastructure. Expansion is expected through a new partnership with a U.S.-based logistics center, which is scheduled to become operational this quarter (Q4 2025, following Q3 reporting). This is being supported by a newly appointed, U.S.-based Head of Commercial Operations for North America. This channel targets the use of rhCollagen in advanced preclinical research and tissue engineering applications.

Licensing agreements for rhCollagen raw material to biomanufacturers

Beyond the AbbVie aesthetic license, the raw material platform itself is a channel through licensing and direct sales to biomanufacturers for research applications. The rhCollagen-based bioink, Collink.3D™, is being positioned as a raw material alternative. The market opportunity for consistent, animal-free biomaterials like Collink.3D™ is estimated at approximately $100 million-dollar market, with an estimated annual growth of over 10%.

The success of this raw material channel is being validated through key research collaborations:

Application/Study	Key Finding/Metric	Date/Context
Collink.3D™ vs. Matrigel®	Outperformed Matrigel® in supporting structured tissue formation.	Reported in Q3 2025.
Mayo Clinic Bioprinting	Used to create the first fully humanized 3D bioprinted skin model.	Reported in Q3 2025.

Scientific publications and conferences for research product awareness

Awareness for the rhCollagen platform, particularly for its use in non-animal testing alternatives, is driven by scientific validation. The findings from the Mayo Clinic and Technion studies serve as powerful awareness tools, demonstrating the platform's utility in creating alternatives to animal testing for preclinical research, drug discovery, and tissue modeling. These results are disseminated through scientific channels, effectively acting as a pull-through mechanism for raw material sales.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Customer Segments

Global medical aesthetics companies seeking next-gen regenerative fillers.

• Exclusive license granted to AbbVie for dermal and soft tissue filler products based on proprietary rhCollagen technology.
• Received a $2 million milestone payment from AbbVie in February 2025.
• The photocurable dermal filler program is advancing toward the clinical stage following preclinical testing.

Pharmaceutical and cosmetic companies needing non-animal testing alternatives.

• The market opportunity for animal-free alternatives, such as Collink.3D™, is approximately $100 million-dollar market.
• This market is estimated to grow over 10% annually.
• Researchers at Mayo Clinic created the first fully humanized bioprinted skin model using rhCollagen as an alternative to animal testing for preclinical research.

Biotechnology and regenerative medicine researchers using 3D bioprinting.

• Successfully 3D bioprinted 200cc commercial-size regenerative breast implants.
• rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in a comparative study supporting structured tissue formation.
• Secured new patents in Japan for rhCollagen-based curable BioInks.

Orthopedic and sports medicine clinics utilizing Vergenix™ STR.

• Vergenix™ STR is marketed primarily in Europe and holds CE Mark approval.
• Expanded distribution in February 2025 to the Netherlands, Belgium, Luxembourg (Benelux), and Spain.
• Expanded distribution in 2025 to Turkey and India, with regulatory processes finalizing.
• Signed a new distribution agreement in Poland in September 2025.

Biomanufacturers requiring clinical-grade, scalable rhCollagen.

• GAAP revenues for the nine months ended September 30, 2025, were $2.3 million, with an increase mainly related to sales of rhCollagen-based products.
• GAAP revenues for the third quarter ended September 30, 2025, were $77,000, compared to $4,000 in Q3 2024, driven by rhCollagen product sales.
• Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new logistics center.

Here's a quick look at the financial scale influencing these customer segments as of late 2025:

Metric	Amount (as of late 2025)
GAAP Revenue (Nine Months Ended Sep 30, 2025)	$2.3 million
GAAP Revenue (Trailing Twelve Months)	$2.48M
GAAP Revenue (Q3 2025)	$77,000
Cash Position (As of March 31, 2025)	$10.7 million
Net Proceeds from June 2025 Offering	$3.1 million
Q3 2025 Net Loss	$3.5 million
Current Market Cap	$28.23M

The company raised $3.1 million in net proceeds from a registered direct offering in June 2025.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Cost Structure

You're looking at the expenses CollPlant Biotechnologies Ltd. incurs to run its business, which centers on developing and commercializing its recombinant human Collagen (rhCollagen) platform. This cost structure reflects a heavy investment in R&D alongside the necessary overhead for a company scaling up commercial efforts, especially in North America.

Operating expenses are a key focus, showing the company's efforts to manage cash burn. For the third quarter ended September 30, 2025, GAAP operating expenses were reported at $3.3 million. This was an improvement, representing a decrease of approximately $1.0 million compared to the same period in 2024. On a non-GAAP basis, which excludes certain non-cash items, operating expenses for Q3 2025 were $3.0 million.

The cost structure is heavily influenced by research and development activities, which are critical for advancing the pipeline:

• High R&D expenses for clinical and preclinical programs, such as the dermal filler and the regenerative breast implant candidates, drive a significant portion of the spend.
• The cost reduction plan implemented by CollPlant Biotechnologies Ltd. specifically targeted R&D. The decrease in Q3 2025 operating expenses included a $519,000 reduction in research and development materials and subcontractors' expenses, largely related to the breast implants program.

Manufacturing and production costs for rhCollagen raw material and final products are embedded within the cost of revenues and operating expenses. While specific, current manufacturing cost breakdowns aren't explicitly detailed as a separate line item here, the focus on rhCollagen sales growth implies ongoing production costs. The company is also focused on expanding its North American distribution, which impacts SG&A and logistics costs.

Sales, General, and Administrative (SG&A) costs are also a major component, especially with the push for North American commercial expansion. The cost-cutting measures also hit personnel-related costs, which fall under SG&A and R&D overhead. Specifically, the Q3 2025 operating expense reduction included a $513,000 decrease in workforce expenses and share-based compensation expenses.

Intellectual property maintenance and legal fees are ongoing requirements for a biotech company protecting its platform technology. These costs are generally captured within the SG&A portion of the operating expenses.

Here's a look at the reported operating expense figures for the periods ending September 30, 2025:

Expense Metric	Period Ended September 30, 2025 Amount (USD)	Period Ended September 30, 2024 Amount (USD)
GAAP Operating Expenses (Q3)	$3.3 million	$4.3 million
Non-GAAP Operating Expenses (Q3)	$3.0 million	$3.8 million
GAAP Operating Expenses (Nine Months)	$10.0 million	$12.3 million
Non-GAAP Operating Expenses (Nine Months)	$9.0 million	$11.0 million

The company is actively managing these outflows. The nine-month GAAP operating expenses through September 30, 2025, totaled $10.0 million. This demonstrates a clear effort to manage the burn rate while advancing key programs.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Revenue Streams

You're looking at how CollPlant Biotechnologies Ltd. brings in cash as of late 2025. It's a mix of upfront payments from big partners and product sales, which is typical for a company at this stage in the regenerative space. Honestly, the milestone payments are the headline drivers right now.

The most concrete revenue source recently came from the strategic collaboration with AbbVie. Following a key development milestone, CollPlant Biotechnologies received a $2 million milestone payment from AbbVie in February 2025, which was recorded in the first quarter of 2025 results. This payment relates to the development and commercialization agreement for dermal and soft tissue filler products using CollPlant's recombinant human collagen (rhCollagen) technology. That single event significantly boosted the top line early in the year.

Here's a quick look at how the revenue built up through the first nine months of 2025:

Period Ended	GAAP Revenue	Key Driver Mentioned
Q1 2025	$2.1 million	$2 million AbbVie milestone payment
Q3 2025	$77,000	Increase in sales of rhCollagen-based products
Nine Months Ended September 30, 2025	$2.3 million	Development milestone from AbbVie agreement

The nine-month 2025 GAAP revenue totaled $2.3 million, definitely a key metric for tracking progress against the prior year's nine-month revenue of $351,000 for the period ended September 30, 2024. That jump shows the impact of the AbbVie payment, but the smaller Q3 revenue suggests product sales are still ramping up.

Beyond the big partnership payments, CollPlant Biotechnologies Ltd. generates revenue from direct sales of its proprietary products. You need to track these streams as they represent the commercial viability of their platform technology:

• Sales of rhCollagen-based products, including the tendon-repair product, Vergenix™ STR. The company is actively expanding the international distribution network for Vergenix™ STR into new markets, including Europe and Asia.
• Sales of Collink.3D™ BioInk for research and bioprinting applications. CollPlant Biotechnologies announced the expansion of its BioInk sales in North America through a new logistics partnership and commercial leadership, aiming to enhance market presence. This bioink is used for things like creating tissue or organ-on-a-chip systems.

Licensing fees and royalties from commercial partners are an expected future stream, though current reports focus on expenses related to royalties. For instance, GAAP cost of revenues for the nine months ended September 30, 2025, included an increase in royalty expenses to the Israel Innovation Authority, mainly related to the $2 million milestone payment received from AbbVie in 2025. This shows that royalty obligations are tied to these upfront payments, with future commercial royalties yet to materialize significantly.

If onboarding takes 14+ days, churn risk rises, but for CollPlant Biotechnologies Ltd., the near-term focus is on converting the success of their bioink in comparative studies-like the one showing Collink.3D™ outperformed Matrigel® in structured tissue formation-into broader research sales. Finance: draft 13-week cash view by Friday.